Recursion · 公司档案
Recursion · 美国 · AI与模型数据
登记关注方向:表型组学、自动化实验、AI药物发现。关注方向是目录字段;具体能力请核查下方来源与项目证据。
别名:Recursion Pharmaceuticals、Exscientia
公开已核验进展
Genentech 将与 Recursion 合作的首个神经科学靶点推进至联合早期发现
Wed Aug 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 条当前公开证据
据 Recursion 官方公告,Genentech 已将双方合作的首个神经科学靶点推进至联合早期发现项目。属于研发阶段进展,不是临床试验结果。
合作、许可与并购时间线
Genentech 将与 Recursion 合作的首个神经科学靶点推进至联合早期发现
Wed Aug 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 条当前公开证据
据 Recursion 官方公告,Genentech 已将双方合作的首个神经科学靶点推进至联合早期发现项目。属于研发阶段进展,不是临床试验结果。
以上来自最新 1 条已核验进展。合作事件成立与模型效果、实验结果或临床进度分别需要证据。
公开原文线索
Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis
Recursion official investor newsroom · 行业原文收录 · 来源发布:Wed Nov 18 2026 09:59:32 GMT+0000 (Coordinated Universal Time) · 本站收录:Wed Nov 18 2026 10:08:16 GMT+0000 (Coordinated Universal Time)
Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis November 18, 2026 at 4:59 AM EST PDF Version REC-4881 is among the first AI-enabled programs to
New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps
Recursion official investor newsroom · 行业原文收录 · 来源发布:Mon Nov 02 2026 21:35:09 GMT+0000 (Coordinated Universal Time) · 本站收录:Mon Nov 02 2026 22:08:25 GMT+0000 (Coordinated Universal Time)
New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps November 2, 2026 at 4:25 PM EST PDF Version Updated TU
Recursion Appoints Fred Hassan as Chair of the Board
Recursion official investor newsroom · 行业原文收录 · 来源发布:Mon Nov 02 2026 21:05:43 GMT+0000 (Coordinated Universal Time) · 本站收录:Mon Nov 02 2026 21:08:02 GMT+0000 (Coordinated Universal Time)
Recursion Appoints Fred Hassan as Chair of the Board November 2, 2026 at 4:05 PM EST PDF Version Salt Lake City, UT , Nov. 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneerin
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3
Recursion official investor newsroom · 行业原文收录 · 来源发布:Mon Oct 26 2026 20:05:29 GMT+0000 (Coordinated Universal Time) · 本站收录:Mon Oct 26 2026 20:07:53 GMT+0000 (Coordinated Universal Time)
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3 October 26, 2026 at 4:05 PM EDT PDF Version Webinar will include earnings updates and REC-4881 data as well as KOL and
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
Recursion official investor newsroom · 行业原文收录 · 来源发布:Thu Oct 15 2026 12:45:47 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Oct 15 2026 13:07:49 GMT+0000 (Coordinated Universal Time)
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration October 15, 2026 at 8:45 AM EDT PDF Version Potential first-in-class dual targeting inhibitor oral sma
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
Recursion official investor newsroom · 行业原文收录 · 来源发布:Thu Oct 15 2026 12:31:00 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Oct 15 2026 13:07:58 GMT+0000 (Coordinated Universal Time)
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock October 15, 2026 at 8:30 AM EDT PDF Version Salt Lake City, UT , Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc.
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
Recursion official investor newsroom · 行业原文收录 · 来源发布:Thu Oct 15 2026 12:22:39 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Oct 15 2026 13:08:02 GMT+0000 (Coordinated Universal Time)
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone October 15, 2026 at 8:22 AM EDT PDF Version Leading Healthcare Investors, includ ing Janus Henderson In
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
Recursion official investor newsroom · 行业原文收录 · 来源发布:Wed Aug 05 2026 10:30:38 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Oct 08 2026 09:07:50 GMT+0000 (Coordinated Universal Time)
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program August 5, 2026 at 6:30 AM EDT PDF Version Genentech advanced the collaboration's first neurosci
已验证的官方与订阅来源
- Recursion official investor newsroom · 采集已启用 · 最近成功 Sun Nov 22 2026 16:08:04 GMT+0000 (Coordinated Universal Time)
来源验证与持续采集分别显示;原文收录不自动成为已核验事件。
专题指南:从原文到判断
按任务比较模型,按证据追踪合作;每篇保留原始出处与更新日期。
虚拟细胞、AI 模型与公司:应该怎样比较?
按输入、输出、任务和验证条件比较单细胞模型、结构预测与蛋白设计,并区分模型论文与公司能力。
阅读指南 · 更新 2026-10-08
AI 制药公司合作时间线:从公告读到证据
用真实官方公告区分合作主体、首付款、条件性里程碑和研发进度,并建立可追溯的合作时间线。
阅读指南 · 更新 2026-10-08
每周 AI 制药信息怎么读:公司动态、研究进展与覆盖缺口
建立每周阅读顺序,分清公告、论文与临床结果;理解本站本周收录的时间窗口、分母和来源覆盖。
阅读指南 · 更新 2026-10-08